Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents (Q37184596)

18 August 2017

1 reference

title

Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents (English)

1 reference

18 August 2017

0 references

Arun Natarajan

1

1 reference

18 August 2017

Azfar G Zaman

series ordinal

2

1 reference

18 August 2017

Sally M Marshall

series ordinal

3

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

Diabetes and Vascular Disease Research

18 August 2017

published in

1 reference

18 August 2017

volume

5

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

138-144

1 reference

Global and societal implications of the diabetes epidemic

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non-ST-elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Diabetes mellitus: a hypercoagulable state

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Diabetes and cardiovascular disease. The Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Effects of glycemic control and other determinants on vascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

The platelet in diabetes: focus on prevention of ischemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Do platelets have anything to do with diabetic microvascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

The evolving role of platelets in inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Platelet dysfunction in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Platelet activation in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Resistance to antiplatelet resistance is it justified?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Aspirin withdrawal increases risk of heart problems

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Narrative review: aspirin resistance and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Aspirin non-responder status in patients with recurrent cerebral ischemic attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Determinants of the interindividual variability in response to antiplatelet drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Clopidogrel: a review of its use in the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.023

21 January 2018

Identifiers

DOI

10.3132/DVDR.2008.023

1 reference

18 August 2017

1 reference